Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $18.3 million.

  • Myriad Genetics' Free Cash Flow rose 75357.14% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.7 million, marking a year-over-year increase of 8249.48%. This contributed to the annual value of -$27.7 million for FY2024, which is 8408.96% up from last year.
  • Per Myriad Genetics' latest filing, its Free Cash Flow stood at $18.3 million for Q3 2025, which was up 75357.14% from -$16.4 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Free Cash Flow ranged from a high of $64.7 million in Q1 2021 and a low of -$64.7 million during Q4 2023
  • Over the past 5 years, Myriad Genetics' median Free Cash Flow value was -$20.5 million (recorded in 2022), while the average stood at -$19.6 million.
  • Per our database at Business Quant, Myriad Genetics' Free Cash Flow tumbled by 53370.79% in 2022 and then surged by 75357.14% in 2025.
  • Myriad Genetics' Free Cash Flow (Quarter) stood at -$12.9 million in 2021, then tumbled by 69.77% to -$21.9 million in 2022, then plummeted by 195.43% to -$64.7 million in 2023, then skyrocketed by 104.64% to $3.0 million in 2024, then skyrocketed by 510.0% to $18.3 million in 2025.
  • Its Free Cash Flow stands at $18.3 million for Q3 2025, versus -$16.4 million for Q2 2025 and -$21.6 million for Q1 2025.